Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy

• Published in: Oncology letters Vol. 15; no. 1; pp. 41 - 47
• Main Authors: Yuan, Jingsheng, Yin, Zhijie, Tao, Kaixiong, Wang, Guobing, Gao, Jinbo
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.01.2018; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Cancer; Cancer therapies; Care and treatment; Cell adhesion & migration; Cell growth; Chemotherapy; Development and progression; Drug resistance; Insulin-like growth factor I; Insulin-like growth factors; Kinases; Oncology; Review; cancer; insulin-like growth factor 1 receptor; mechanisms; chemotherapeutic resistance; review
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2017.7276

Drug resistance is a primary cause of chemotherapeutic failure; however, how this resistance develops is complex. A comprehensive understanding of chemotherapeutic resistance mechanisms may aid in identifying more effective drugs and improve the survival rates of patients with cancer. Insulin-like growth factor 1 receptor (IGF1R), a member of the insulin receptor family, has been extensively assessed for biological activity, and its putative contribution to tumor cell development and progression. Furthermore, researchers have attended to drugs that target IGF1R since IGF1R functions as a membrane receptor. However, how IGF1R participates in chemotherapeutic resistance remains unclear. Therefore, the present study described the gene and its associated signaling pathways, and offered details of IGF1R-induced tumor chemoresistance associated with promoting cell proliferation, inhibition of apoptosis, regulation of ATP-binding cassette transporter proteins and interactions with the extracellular matrix. The present study offered additional explanations for tumor chemotherapy resistance and provided a theoretical basis of IGF1R and its downstream pathways for future possible chemotherapy treatment options.